Intrinsic Value of S&P & Nasdaq Contact Us

Orexo AB (publ) ORXOF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • SE • USD

SharesGrow Score
18/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Orexo AB (publ) (ORXOF) generated $150.72M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $150.72M.

Free cash flow margin was 4578.8% of revenue. Cash conversion ratio was -1.31x, suggesting some earnings are non-cash.

Criteria supported by this page:

  • HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
  • INCOME (10/100) — Cash conversion ratio was -1.31x suggests some earnings are non-cash items

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
18/100
SG Score
View full scorecard →
VALUE
N/A
No coverage
FUTURE
N/A
No coverage
PAST
0/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
0/100
Proven by this page
GROWTH
30/100
→ Income
INCOME
10/100
→ Income
Orexo AB (publ) Cash Flow History
Metric TTM Q4 FY2025 Q2 FY2025 Q1 FY2025 Q4 FY2024
Operating Cash Flow $189.12M$150.72M$-700K$32.9M$6.2M
Capital Expenditure $-800K$0.00$0.00$0.00$-800K
Free Cash Flow $188.32M$150.72M$-700K$32.9M$5.4M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message